Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin receptor antagonism for treatment of insomnia
W. Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Neurology (2012) Vol. 79, Iss. 23, pp. 2265-2274
Closed Access | Times Cited: 298

Showing 26-50 of 298 citing articles:

Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Headache and sleep: Shared pathophysiological mechanisms
Philip R. Holland
Cephalalgia (2014) Vol. 34, Iss. 10, pp. 725-744
Closed Access | Times Cited: 104
Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis
Almira Chabi, Ying Zhang, Saheeda Jackson, et al.
Cephalalgia (2014) Vol. 35, Iss. 5, pp. 379-388
Closed Access | Times Cited: 103
In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 2, pp. 287-295
Open Access | Times Cited: 89
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
Zolpidem: Efficacy and Side Effects for Insomnia
Amber N. Edinoff, Natalie W. Wu, Yahya T. Ghaffar, et al.
Health psychology research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 55
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper
Andrew S. Huhn, Patrick H. Finan, Charlene E. Gamaldo, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 650
Closed Access | Times Cited: 50
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 98
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
Anthony L. Gotter, Christopher J. Winrow, Joseph Brunner, et al.
BMC Neuroscience (2013) Vol. 14, Iss. 1
Open Access | Times Cited: 88
Evidence for orexinergic mechanisms in migraine
Jan Hoffmann, Weera Supronsinchai, Simon Akerman, et al.
Neurobiology of Disease (2014) Vol. 74, pp. 137-143
Closed Access | Times Cited: 83
New strategies for the treatment and prevention of primary headache disorders
Nathaniel M. Schuster, Alan M. Rapoport
Nature Reviews Neurology (2016) Vol. 12, Iss. 11, pp. 635-650
Closed Access | Times Cited: 83
An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics
Kayla Janto, J. Roxanne Prichard, Snigdha Pusalavidyasagar
Journal of Clinical Sleep Medicine (2018) Vol. 14, Iss. 08, pp. 1399-1408
Open Access | Times Cited: 81
The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry
Quanhui Chen, Luı́s de Lecea, Zhian Hu, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 152-197
Closed Access | Times Cited: 79
Selective orexin receptor antagonists
Terry P. Lebold, Pascal Bonaventure, Brock T. Shireman
Bioorganic & Medicinal Chemistry Letters (2013) Vol. 23, Iss. 17, pp. 4761-4769
Closed Access | Times Cited: 73
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Taro Kishi, Shinji Matsunaga, Nakao Iwata
PLoS ONE (2015) Vol. 10, Iss. 8, pp. e0136910-e0136910
Open Access | Times Cited: 72
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
Anthony L. Gotter, Mark S. Forman, C. Meacham Harrell, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 72
Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials
W. Joseph Herring, Kathleen M. Connor, Ellen Snyder, et al.
Journal of Clinical Sleep Medicine (2016) Vol. 12, Iss. 09, pp. 1215-1225
Open Access | Times Cited: 71
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Aiding sleep in type 2 diabetes: therapeutic considerations
Xiao Tan, Lieve van Egmond, Colin D. Chapman, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 6, Iss. 1, pp. 60-68
Closed Access | Times Cited: 69
Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea
Hong Sun, John Palcza, Deborah Card, et al.
Journal of Clinical Sleep Medicine (2016) Vol. 12, Iss. 01, pp. 9-17
Open Access | Times Cited: 67
Suvorexant
Kunal V. Patel, Anthony V. Aspesi, Kirk E. Evoy
Annals of Pharmacotherapy (2015) Vol. 49, Iss. 4, pp. 477-483
Closed Access | Times Cited: 65

Scroll to top